← Back to all trials
Not Yet Recruiting
NCT07792395
Ginger's Therapeutic Potential in Asthma
Conditions: Asthma
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE2
Enrollment: 32
Sponsor: Emily DiMango, MD
Location: Columbia University Asthma Center New York New York
Summary
Primary Objective: The primary endpoint is a clinically significant improvement in tolerance to inhaled methacholine (PD20).
Secondary Objectives: 1) To determine if oral daily ginger extract intake - decreases fractional excretion of nitric oxide; decreases blood eosinophilia; decreases asthma-associated cytokines in serum; decreases medium chain fatty acids; improves asthma symptoms; and 2) Establish pharmacokinetic parameters of biologically active components of ginger in adult asthmatics.
Eligibility Criteria
Inclusion Criteria:
1. Adults aged 18 years or older with mild to severe persistent asthma as defined by NIH National Asthma Education and Prevention Program (NAEPP) guidelines, with asthma that is not optimally controlled despite current use of inhaled corticosteroids with or without inhaled long-acting beta agonists.
2. Treatment with inhaled corticosteroids (ICS), with or without long-acting beta-agonists/long-acting muscarinic antagonists and montelukast.
3. Physician-diagnosed asthma confirmed by history/report, pulmonary function testing with FEV1 ≥60% predicted or ≥1.5 L, and methacholine testing with baseline methacholine PD20 \
Source: ClinicalTrials.gov (NCT07792395). StuddyBuddy aggregates publicly available trial information.
